T cells can be induced to specifically lyse tumor cells with bispecific antibodies containing
anti-T cell receptor mAbs crosslinked to anti-tumor mAbs. Such «targeted cytolysis» requires …

Abstract Bispecific F (ab′ γ) 3 derivatives have been constructed by selective coupling of
monoclonal antibody Fab′ γ fragments, using the cross‐linker o‐phenylenedimaleimide …

We report the simultaneous use of europium-DTPA (Eu-DTPA) and samarium-DTPA (Sm-
DTPA) in cytotoxicity experiments to analyze simultaneously LAK and NK cell lysis and to …

The role of activated T cells in the mediation of antitumor responses has been documented
in several experimental models. In some of these, interleukin-2 (IL-2) has been used as a …

This report focuses on cell-mediated immune functions in a patient with MHC class II
deficiency. The patient described presented with a case of “classical” MHC class II …

Immunotherapy has been developed for the treatment of metastatic cancers refractory to
conventional therapies. Immunotherapy utilizes immune cells and/or biological response …

Although T cell receptors and Fc receptors are the best known cytotoxic triggering
molecules, a number of adhesion molecules recently have been identified as alternative …

Bispecific monoclonal antibodies, with a dual specificity for tumor associated antigens on
target cells and for surface markers on immune effector cells, have been shown (in vitro) to …

The 38C13 murine lymphoma model was used to examine the role T cell activation plays in
anti-CD3-based bispecific antibody therapy by comparing two bispecific antibody …

Bispecific antibodies are currently being used in clinical trials in increasing numbers in the
areas of breast cancer, prostate cancer, non-Hodgkin's lymphoma and Hodgkin's lymphoma …